Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients

Blood

Volumn 97, Issue 2, 2001, Pages 388-392

  Ljungman, Per ^a   Deliliers, Giorgio Lambertenghi ^b   Platzbecker, Uwe ^b   Matthes Martin, Susanne ^b   Bacigalupo, Andrea ^b   Einsele, Hermann ^b   Ullmann, Johanna ^b   Musso, Maurizio ^b   Trenschel, Rudolf ^b   Ribaud, Patricia ^b   Bornhäuser, Martin ^b   Cesaro, Simone ^b   Crooks, Bruce ^b   Dekker, Adrian ^b   Gratecos, Nicole ^b   Klingebiel, Thomas ^b   Tagliaferri, Elena ^b   Ullmann, Andrew J ^b   Wacker, Pierre ^b   Cordonnier, Catherine ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; PROBENECID;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; MALE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEWBORN; OPHTHALMOPLEGIA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SYNCOPE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VERTIGO; VIRUS INFECTION;

EID: 0035863827     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.2.388     Document Type: Article

References (34)

1. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients
2. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS
3. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: A randomized, controlled trial
4. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC peripheral cytomegalovirus retinitis trial: A randomized, controlled trial
5. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir
6. A three center European external quality control study of PCR for detection of cytomegalovirus DNA in blood
7. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
8. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive therapy in allogeneic bone marrow transplant recipients
9. Rapid detection and quantification of active cytomegalovirus infection by monocional antibody staining of blood leucocytes
10. Definitions of cytomegalovirus infection and disease
11. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin
12. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: Experience of European Bone Marrow Transplant Group
13. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants
14. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients
15. Cytomegalovirus pneumonia after bone marrow transplantation: Risk factors and response to the therapy
16. CMV infections following allogeneic BMT: Risk factors, early treatment and correlation with transplant related mortality
17. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients
18. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: A report from the European Group for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party of the EBMT
19. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients: A randomized, placebo-controlled trial
20. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct)
21. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
22. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant recipients
23. Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): A randomised study
24. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
25. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome
26. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients
27. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections
28. Hypotony and visual loss with intravenous cidofovir treatment of cytomegalovirus retinitis
29. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis
30. Recurrent iritis after intravenous administration of cidofovir
31. Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis
32. Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment el cytomegalovirus retinitis: Analysis and prevention
33. Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient